Relapsed Diffuse Large B-Cell Lymphoma Clinical Trials

24 clinical trials for Relapsed Diffuse Large B-Cell Lymphoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU — RECRUITING
• DALY II USA/ MB-CART2019.1 for DLBCL — RECRUITING · PHASE2
• Epcoritamab-CAR T Cells for Large B-cell Lymphomas — RECRUITING · PHASE2
• A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies — RECRUITING · PHASE1
• DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE2
• An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant — COMPLETED · PHASE2
• A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) — COMPLETED · PHASE2
• Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) — COMPLETED · PHASE3
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib — COMPLETED · PHASE2
• Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL — ACTIVE_NOT_RECRUITING
• Copanlisib Plus Venetoclax in R/R DLBCL — ACTIVE_NOT_RECRUITING · PHASE1
• Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) — ACTIVE_NOT_RECRUITING · PHASE2
• Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab — COMPLETED · PHASE1
• A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma — TERMINATED · PHASE1
• Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) — COMPLETED · PHASE1
• Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant — WITHDRAWN · PHASE2
• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL — COMPLETED · PHASE1
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy — TERMINATED · PHASE2
• PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma — TERMINATED · PHASE2
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE1
• Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL — OTHER · PHASE2
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE1

Refine this search